Zhejiang Ausun Pharmaceutical Co., Ltd. Class A

Zhejiang Ausun Pharmaceutical Co., Ltd. Class A

SSSE:603229
6.71
CNY
-0.02
(-0.30%)
-0.01EPS
6.86BMarket Cap
Apr 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.59
0.91
0.52
0.36
0.36
0.33
0.41
0.55
0.72
0.95
1
0.96
0.97
0.92
Basic EPS, GAAP
0.08
0.1
0.12
0.1
0.08
0.06
0.08
0.12
0.18
0.29
0.31
0.25
0.16
-0.01
Free Cash Flow per Basic Share
-0.1
-0.01
0.02
0.09
-0.01
-0.06
0.05
0.06
-0.17
-0.19
0.07
0.08
0.06
- -
Dividend per Share
0.02
0.02
0.01
0.01
- -
0.02
0.02
0.02
0.03
0.05
0.07
0.1
0.11
0.08
Book Value per Share
0.15
0.36
0.45
0.44
0.77
0.81
0.87
1.43
1.59
1.86
2.58
2.74
2.73
2.76
Tangible Book Value per Share
-0.02
0.19
0.36
0.37
0.72
0.76
0.83
1.36
1.39
1.66
2.4
2.55
2.55
2.58
Basic Weighted Avg Shares
205
220
501
551
660
749
743
745
795
804
819
827
816
820
Sales/Revenue/Turnover
121
201
263
199
240
244
308
409
570
765
817
795
793
757
Operating Margin (%)
20.28
17.53
27.77
28.73
32.41
12.51
19.39
29.48
28
28
32.09
25.89
17.49
4.09
Depreciation Expense
8
11
11
15
18
21
23
25
30
34
41
64
74
- -
Net Income, GAAP
16
22
61
57
53
44
56
87
146
235
254
207
131
-5
Effective Tax Rate (%)
14.88
21.73
13.38
12.15
11.86
7.31
6.96
9.07
8.45
8.01
12.68
13.91
5.32
- -
Profit Margin (%)
12.86
10.67
23.17
28.83
22.07
17.99
18.31
21.22
25.62
30.79
31.09
26
16.47
-0.6
Working Capital
-70
-71
9
54
339
340
369
736
490
391
904
1,035
1,079
1,098
LT Debt
27
- -
5
13
- -
- -
- -
- -
45
73
2
1
44
22
Total Equity
33
78
188
243
565
598
645
1,127
1,255
1,461
2,142
2,272
2,269
2,288
Return on Invested Capital (%)
19.18
15.76
27.83
20.04
12.24
7.12
8.41
9.47
11.55
15.45
12.23
8.32
5.04
- -
Return on Capital (%)
24.12
19.8
32.51
21.93
12.72
7.57
8.64
9.48
11.63
15.71
12.58
8.56
5.25
- -
Return on Common Equity (%)
71.9
38.7
45.71
26.58
13.12
7.55
9.07
9.8
12.25
17.33
14.1
9.37
5.75
-0.19

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
442
317
293
LT Borrowings
44
44
22
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
830
830
830
Market Capitalization
8,403
6,426
6,858

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,879
1,781
1,631
Cash, Cash Equivalents & STI
1,154
1,004
955
Accounts Receivable, Net
317
357
253
Inventories
368
370
374
Total Current Liabilities
711
602
533
Payables & Accruals
- -
- -
- -
ST Debt
442
317
293
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
33.03%
16.07%
-0.11%
Free Cash Flow
31%
-107.33%
-21.85%
Net Income, GAAP
13.38%
16.36%
-36.86%
Sales/Revenue/Turnover
13.45%
15.46%
-0.32%
Total Cash Common Dividend
60.43%
48.88%
7.61%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
301
191
198
105
795
2025
307
175
- -
147
793
2026
309
159
143
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.08
0.06
-0.03
0.25
2025
0.14
0.06
- -
-0.09
0.16
2026
0.12
0.03
-0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.09
- -
0.1
2025
- -
- -
- -
- -
0.11
2026
- -
- -
0.07
- -
- -

Company Description

CEO
Zhi Guo Zheng
Full Time Employees
1,328
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 5 Donghai Fourth Lane Taizhou China 317016
IPO Date
May 9, 2017
Business
Zhejiang Ausun Pharmaceutical Co., Ltd. engages primarily in the research, development, manufacturing, and sale of pharmaceutical products and healthcare-related solutions. The company's core offerings include cardiovascular medications; diabetes treatment drugs; digestive system therapeutics; anti-inflammatory and analgesic agents; traditional Chinese medicine formulations; biochemical reagents; and health supplements. It serves both hospital and retail pharmacy markets with a diversified product portfolio across these therapeutic areas. The company operates predominantly in China, with its headquarters based in Zhejiang Province, where it was founded. In the last 1-2 years, Zhejiang Ausun Pharmaceutical has focused on strengthening its R&D capabilities and expanding its product development pipeline, notably launching new drugs in key therapeutic segments such as cardiovascular and metabolic diseases. It has formed strategic partnerships with research institutions and biotechnology firms to innovate in drug formulation and to accelerate commercialization of advanced pharmaceutical products. Additionally, the company has invested in upgrading its manufacturing processes to comply with international standards, aiming to enhance product quality and scale its geographic reach. No major name changes or corporate reorganizations have been reported during this period. Zhejiang Ausun Pharmaceutical operates within the pharmaceutical industry, targeting healthcare providers, hospitals, and pharmaceutical distributors in the Chinese market. It was established in 1997 and is listed on the Shanghai Stock Exchange under ticker 603229.SS. The company maintains several subsidiaries that support its operations in research, manufacturing, and distribution, reflecting its vertical integration strategy to control the supply chain and enhance market responsiveness. Overall, Zhejiang Ausun adheres to a model focused on innovation-driven growth in specialized pharmaceutical products for chronic and acute disease management.